Emergency Warning Signs: Macrophage Activation Syndrome (MAS)
At a Glance
Macrophage activation syndrome (MAS) is a life-threatening complication of systemic JIA that can worsen within hours or days. Seek emergency care for severe sleepiness, breathing trouble, bleeding, abdominal swelling, persistent fever, or worsening lab trends—even if biologic medicines reduce fever.
Macrophage Activation Syndrome (MAS) is the most serious and life-threatening complication of systemic juvenile idiopathic arthritis (sJIA) [1]. It is a state of extreme immune dysregulation where the immune system’s “clean-up cells,” called macrophages, become overactive and cause severe secondary damage to the body’s own tissues and blood cells [2].
MAS can develop very quickly—sometimes within hours or days—and requires immediate hospitalization and intensive treatment [3]. As a parent, you are often the first to notice the subtle clinical shifts that signal the start of this emergency.
EMERGENCY ACTION PLAN: When to Seek Help
Do not wait for a high fever or a specific lab result if your child looks severely ill. If your child has a known or suspected sJIA diagnosis and develops any of the following symptoms, follow your rheumatology team’s written emergency plan or seek emergency medical care immediately:
- Neurological Changes: Unusual lethargy (extreme sleepiness and inability to wake up), confusion, irritability, or even seizures [3].
- Signs of Organ Distress: Difficulty breathing, feeling very faint (shock-like symptoms), yellowing of the skin or eyes (jaundice), or a significant drop in how much your child is urinating [3].
- Easy Bruising or Bleeding: Small red or purple spots on the skin (petechiae), spontaneous nosebleeds, or bleeding gums [3][1].
- Extreme Abdominal Symptoms: Severe pain or a visible swelling of the belly, which may be caused by a rapidly enlarging liver or spleen [1].
- Change in Fever Pattern: Instead of the typical sJIA “daily spike,” the fever becomes persistent, staying high throughout the day and night [3].
The Lab Red Flags: Falling Counts, Rising Risk
In many medical conditions, “falling” numbers in a blood test are a sign of improvement. In MAS, the opposite is often true. Doctors look for specific shifts in laboratory values to catch MAS in its early stages, because there is no single number that definitively rules MAS in or out [4].
A major warning sign is when values that are usually high during a flare suddenly start to drop while the child is getting sicker:
- Falling Platelets: Platelets help the blood clot. A sudden drop (even if they are still within the “normal” range) is a hallmark of MAS [5].
- Falling ESR and Fibrinogen: The ESR (sedimentation rate) and fibrinogen are markers of inflammation that are typically high in sJIA. In MAS, an unexpected drop despite active inflammation can be a clue that the body is consuming them too fast [5][4].
- Rising Ferritin: This protein, which stores iron, can become extremely high. While a rapidly rising or very high ferritin is concerning, the exact cutoff varies [6].
- Rising Liver Enzymes (AST/ALT): These indicate the liver is under stress or being affected by the immune system [6].
The “Masking” Effect of Biologic Treatments
If your child is taking biologic medications like tocilizumab (an IL-6 inhibitor) or anakinra (an IL-1 inhibitor), the “typical” signs of MAS may be hidden [7].
These drugs are very effective at blocking the signals that cause fever and high ferritin. This means a child on these treatments could be developing MAS without a high fever and with only a modestly elevated ferritin level [8][7].
Because these treatments “blunt” the usual symptoms, doctors cannot rely on standard diagnostic checklists alone. They must look at the trends of the labs over time [9][10]. If the labs are trending in the wrong direction—such as platelets dropping day by day—it is treated as an emergency even if the child doesn’t “look” like they have MAS on paper [5].
Monitoring and Early Action
Because MAS can progress so rapidly, your rheumatology team will likely perform serial lab monitoring (frequent, repeated blood tests) whenever your child is having a flare or starting a new medication [4]. This allows them to see the “slope” of the change before the numbers reach a dangerous level.
Never hesitate to go to the emergency room because you are worried about “masking,” and do not independently stop or change your child’s biologic or steroid dose. It is always safer to have your child’s labs checked than to wait when clinical signs like lethargy or bruising appear [3]. Early intervention with high-dose steroids or specialized medications is the key to successfully managing an MAS episode [11].
Common questions in this guide
Which symptoms of MAS mean my child needs emergency care?
Can biologic medicines hide the usual signs of MAS?
What lab changes can suggest MAS even if individual results seem normal?
Why might a lower ESR be concerning during an sJIA flare?
What should I do if I think my child may be developing MAS?
How is macrophage activation syndrome treated in children with sJIA?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Since my child is on a biologic (IL-1 or IL-6 inhibitor), what specific lab trends should I watch for that might be more reliable than fever?
- 2.Can we review my child's baseline lab values (platelets, ferritin, AST) so I know what 'normal' looks like for them during a flare versus health?
- 3.If I suspect MAS is starting, what is our emergency action plan, and who should I call after hours?
- 4.Does our local hospital have experience managing MAS, or is there a protocol to transfer my child to a specialist center if this occurs?
- 5.In the context of MAS, why is a falling ESR (sedimentation rate) sometimes a concerning sign rather than a sign of improvement?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (11)
- 1
Macrophage activation syndrome in systemic juvenile idiopathic arthritis.
Shimizu M
Immunological medicine 2021; (44(4)):237-245 doi:10.1080/25785826.2021.1912893.
PMID: 33982649 - 2
Genetics of Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis.
Grom AA
Advances in experimental medicine and biology 2024; (1448()):121-126 doi:10.1007/978-3-031-59815-9_9.
PMID: 39117811 - 3
Case Report: Refractory macrophage activation syndrome requiring high-dose anakinra, emapalumab, and etoposide therapy in early-onset systemic juvenile idiopathic arthritis associated with adenoviremia.
Slaney ED, Modica R, Woolnough L, et al.
Frontiers in pediatrics 2023; (11()):1336554 doi:10.3389/fped.2023.1336554.
PMID: 38322244 - 4
Macrophage activation syndrome: early diagnosis is key.
Lerkvaleekul B, Vilaiyuk S
Open access rheumatology : research and reviews 2018; (10()):117-128 doi:10.2147/OARRR.S151013.
PMID: 30214327 - 5
Single center clinical analysis of macrophage activation syndrome complicating juvenile rheumatic diseases.
Huang S, Liu Y, Yan W, et al.
Pediatric rheumatology online journal 2024; (22(1)):58 doi:10.1186/s12969-024-00991-3.
PMID: 38783316 - 6
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.
Ravelli A, Minoia F, Davì S, et al.
Annals of the rheumatic diseases 2016; (75(3)):481-9 doi:10.1136/annrheumdis-2015-208982.
PMID: 26865703 - 7
Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis.
Schulert GS, Minoia F, Bohnsack J, et al.
Arthritis care & research 2018; (70(3)):409-419 doi:10.1002/acr.23277.
PMID: 28499329 - 8
Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
Shimizu M, Mizuta M, Okamoto N, et al.
Pediatric rheumatology online journal 2020; (18(1)):2 doi:10.1186/s12969-020-0399-1.
PMID: 31924225 - 9
Validation of Classification Criteria of Macrophage Activation Syndrome in Japanese Patients With Systemic Juvenile Idiopathic Arthritis.
Shimizu M, Mizuta M, Yasumi T, et al.
Arthritis care & research 2018; (70(9)):1412-1415 doi:10.1002/acr.23482.
PMID: 29195002 - 10
Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis on anti-interleukin-1 or -6 therapy.
Ulu K, Aliyev E, Kılıç Könte E, et al.
Rheumatology (Oxford, England) 2024; (63(SI2)):SI167-SI172 doi:10.1093/rheumatology/keae124.
PMID: 38441301 - 11
Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
Boom V, Anton J, Lahdenne P, et al.
Pediatric rheumatology online journal 2015; (13()):55 doi:10.1186/s12969-015-0055-3.
PMID: 26634252
This page is for informational purposes only and does not constitute medical advice about your child's condition. If you suspect MAS or your child looks seriously ill, follow the rheumatology team's emergency plan or seek emergency medical care immediately.
Get notified when new evidence is published on Systemic-onset juvenile idiopathic arthritis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.